Discovery vct 690 pet ct

Manufactured by GE Healthcare

Sourced in United States

The Discovery VCT 690 PET/CT is a combined positron emission tomography (PET) and computed tomography (CT) imaging system developed by GE Healthcare. It is designed to acquire high-quality images for clinical diagnostic and research applications.

Automatically generated - may contain errors

Lab products found in correlation

Discovery mi pet ct, by GE Healthcare (5 mentions) Signa pet mr, by GE Healthcare (3 mentions) Discovery mr750w, by GE Healthcare (1 mentions)

7 protocols using discovery vct 690 pet ct

Optimized PET/CT Imaging of PSMA

Check if the same lab product or an alternative is used in the 5 most similar protocols

Patients received a single injection of ⁶⁸ Ga-PSMA (mean dose ± standard deviation, 130 ± 11 MBq, range 114–158 MBq) 60 min prior to image acquisition. To reduce tracer activity in the bladder, ureters, and kidneys, furosemide was injected intravenously 30 min prior to the radiotracer injection (0.13 mg/kg), patients drank 200 mL of water prior to radiotracer injection, and patients were asked to void prior to the scan. PET/CT acquisitions were performed on a Discovery VCT 690 PET/CT (GE Healthcare) (n = 38) or on a Discovery MI PET/CT (GE Healthcare) (n = 29) with six-bed positions (2.5 min acquisition time). CT as part of PET/CT was performed using the following scan parameters: tube voltage 140 kVp, tube current with automated dose modulation of 80 mA/slice, collimation 512 × 0.976, pitch 1.0, rotation time 0.5 s, coverage speed 78 mm/s, field of view (FOV) 50 cm. Images with a transverse pixel size of 1.00 and a slice thickness of 1.25 mm were reconstructed in the axial plane using the standard kernel.

Hinzpeter R., Baumann L., Guggenberger R., Huellner M., Alkadhi H, & Baessler B. (2021). Radiomics for detecting prostate cancer bone metastases invisible in CT: a proof-of-concept study. European Radiology, 32(3), 1823-1832.

+ Open protocol

+ Expand

PSMA-11 PET/CT and PET/MR Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols

Patients had undergone clinical routine ⁶⁸Ga-PSMA-11-PET/computed tomography (CT) on a Discovery VCT 690 PET/CT (GE Healthcare, Waukesha, WI, USA) or on a Discovery MI PET/CT (GE Healthcare, Waukesha, WI, USA) or ⁶⁸Ga-PSMA-11-PET/magnetic resonance (MR) (SIGNA PET/MR, GE Healthcare, Waukesha, WI, USA) after a single injection of ⁶⁸Ga-PSMA-11 (mean dose ± standard deviation (SD) 130 ± 18 MBq, range 81-171 MBq). The institutional protocol is in agreement with the EANM and SNMMI procedure guidelines 24 . Details are given in the supplements.

Ferraro D.A., Rüschoff J.H., Muehlematter U.J., Kranzbühler B., Müller J., Messerli M., Husmann L., Hermanns T., Eberli D., Rupp N.J, & Burger I.A. (2020). Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68Ga-PSMA-11-PET. Theranostics, 10(14), 6082-6094.

+ Open protocol

+ Expand

Prostate Cancer Imaging with 68Ga-PSMA-11 PET/CT and PET/MRI

Check if the same lab product or an alternative is used in the 5 most similar protocols

Patients underwent clinical routine ⁶⁸Ga-PSMA-11-PET/computed tomography (CT) on a Discovery VCT 690 PET/CT (GE Healthcare, Waukesha, WI, USA) or on a Discovery MI PET/CT (GE Healthcare, Waukesha, WI, USA) or ⁶⁸Ga-PSMA-11-PET/MRI (SIGNA PET/MR, GE Healthcare, Waukesha, WI, USA) after a single injection of ⁶⁸Ga-PSMA-11 (mean dose ± standard deviation (SD) 130 ± 18 MBq, range 81–171 MBq). The institutional protocol is in agreement with the EANM and SNMMI procedure guidelines [26 (link)]. Details are given in the supplements.

Rüschoff J.H., Ferraro D.A., Muehlematter U.J., Laudicella R., Hermanns T., Rodewald A.K., Moch H., Eberli D., Burger I.A, & Rupp N.J. (2021). What’s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns. European Journal of Nuclear Medicine and Molecular Imaging, 48(12), 4042-4053.

+ Open protocol

+ Expand

PSMA-11 PET/CT and PET/MRI Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols

All patients underwent clinical routine [ 68 Ga]Ga-PSMA-11 PET/computed tomography (CT) (Discovery VCT 690 PET/ CT (GE Healthcare, Waukesha, WI, USA) or Discovery MI PET/CT (GE Healthcare, Waukesha, WI, USA)) or a [ 68 Ga] Ga-PSMA-11 PET/MRI (SIGNA PET/MR, GE Healthcare, Waukesha, WI, USA) after a single injection of [ 68 Ga]Ga-PSMA-11 (2 MBq / kg) as described previously [3] .

Rupp N.J., Freiberger S.N., Ferraro D.A., Laudicella R., Heimer J., Muehlematter U.J., Poyet C., Moch H., Eberli D., Rüschoff J.H, & Burger I.A. (2024). Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [⁶⁸Ga]Ga-PSMA-11 PET scans of primary prostate cancer. European journal of nuclear medicine and molecular imaging.

+ Open protocol

+ Expand

Standardized 68Ga-PSMA-11 PET/CT Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols

For patients who underwent ⁶⁸Ga-PSMA-11 PET/CT, PET was performed with six bed positions with 2.5 min acquisition time per bed position and an attenuation CT scan was acquired on a Discovery VCT 690 PET/CT (GE Healthcare, Waukesha, WI, USA) or on a Discovery MI PET/CT (GE Healthcare, Waukesha, WI, USA) 60 min after injection with whole-body scan parameters as follows: tube voltage 140 kV, tube current with automated dose modulation with a maximum of 80 mA/slice, collimation 512 × 0.976, pitch 0.984:1, rotation time 0.5 s, coverage speed 78 mm/s, field of view (FOV) 50 cm, and images with a transverse pixel size of 0.976 and a slice thickness of 1.25 mm reconstructed in the axial plane.

Fassbind S., Ferraro D.A., Stelmes J.J., Fankhauser C.D., Guckenberger M., Kaufmann P.A., Eberli D., Burger I.A, & Kranzbühler B. (2021). 68Ga-PSMA-11 PET imaging in patients with ongoing androgen deprivation therapy for advanced prostate cancer. Annals of Nuclear Medicine, 35(10), 1109-1116.

+ Open protocol

+ Expand

Optimizing NSCLC Tumor Size Analysis

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

The CT system consisted of a full-ring time-of-flight 64-slice positron emission tomography (PET)/CT scanner (Discovery PET/CT 690 VCT; GE Healthcare, Chicago, IL, USA). The CT diagnosis system was used to analyze NSCLC tumor size using the preprogrammed setting. The preprogrammed setting was optimized, as described previously (17 (link)) to achieve the best image formation. The lungs in all patients underwent contrast-enhanced CT according to the manufacturer's protocols (Discovery PET/CT 690 VCT). The Tumor-Node-Metastasis (TNM) stage (seventh edition) (18 (link)) was assigned based on intraboard consensus decision.

Cheng M., Sun X., Liu G., Cheng K., Lv Z., Sun C., Xiu D, & Liu L. (2018). Comprehensive analysis of marker gene detection and computed tomography for the diagnosis of human lung cancer. Oncology Letters, 16(4), 4400-4406.

+ Open protocol

+ Expand

Trimodality PET/CT/MR System Workflow

Check if the same lab product or an alternative is used in the 5 most similar protocols

The trimodality PET/CT/MR system consists of a full-ring time-offlight 64-slice PET/CT scanner (Discovery PET/CT 690 VCT; GE Healthcare) and a 3-T MR scanner (Discovery MR 750w; GE Healthcare), connected by a shuttle system (5, 13, 14) . Patients fasted at least 4 h before being injected with 350 MBq of 18 F-FDG. The total uptake time was 60 min. After 40 min, patients were transferred into the MR machine. All MR images were acquired during these 20 min. Then patients were transferred to the PET/CT machine, where acquisition started subsequently. Details are given in the supplemental materials (available at http://jnm.snmjournals.org).

Huellner M.W., de Galiza Barbosa F., Husmann L., Pietsch C.M., Mader C.E., Burger I.A., Stolzmann P., Delso G., Frauenfelder T., von Schulthess G.K, & Veit-Haibach P. (2016). TNM Staging of Non-Small Cell Lung Cancer: Comparison of PET/MR and PET/CT. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 57(1).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!